AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12871894
Drug: estradiol 2
RxNorm normalized name: estradiol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA)
Trial: 10870872
Drug: Zaleplon 5
RxNorm normalized name: zaleplon 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon 5 mg
Trial: 6230950
Drug: Atracurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.2 mg/kg for muscle relaxation
Trial: 29083530
Drug: 200 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg/mL amphotericin B nasal irrigation
Trial: 15675987
Drug: Continuous physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous physostigmine infusion combined with morphine-based PCA
Trial: 12166337
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg ramosetron intravenously
Trial: 10381905
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg aspirin daily for 3 months
Trial: 10381905
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg aspirin daily for 3 months
Trial: 10381905
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin daily for 3 months
Trial: 1844773
Drug: Cefuroxime (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (250 mg td) for 7 days
Trial: 1844773
Drug: Trimethoprim sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim sulfamethoxazole (160/800 mg td) for 7 days
Trial: 6557966
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Fenoterol orally before 0.4 mg PGE2 gel
Trial: 6557966
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg PGE2 gel
Trial: 6557966
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg PGE2 gel
Trial: 26762497
Drug: 2-octyl cyanoacrylate
RxNorm normalized name: 2-octyl cyanoacrylate
DrugBank: 2-octyl cyanoacrylate (DB12040)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-octyl cyanoacrylate with Opsite (G+O)
Trial: 26762497
Drug: 2-octyl cyanoacrylate
RxNorm normalized name: 2-octyl cyanoacrylate
DrugBank: 2-octyl cyanoacrylate (DB12040)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-octyl cyanoacrylate with Tegaderm (G+T)
Trial: 21415284
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate 2400 mg
Trial: 21415284
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg (single dose)
Trial: 15379365
Drug: EE/DRSP (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/DRSP (30 microg ethinyl estradiol and 3 mg drospirenone)
Trial: 15379365
Drug: EE/NGM (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/NGM (35 microg ethinyl estradiol and 0.180, 0.215, 0.250 mg norgestimate)
Trial: 11307411
Drug: Laser-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-assisted therapy (diode laser light, 1-watt output, maximum of 20 seconds)
Trial: 8398517
Drug: Amethocaine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amethocaine patch (30-min application)
Trial: 8398517
Drug: Amethocaine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amethocaine patch (60-min application)
Trial: 8398517
Drug: Amethocaine gel
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amethocaine gel preparation
Trial: 28728744
Drug: Beta Blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta Blocker (BB) use at ≥50% target dose
Trial: 25789519
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (2.0 mg of 17β‐estradiol)
Trial: 25789519
Drug: Estrogen‐progestin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen‐progestin therapy (2.0 mg of 17 β‐estradiol + 1.0 mg of norethisterone acetate)
Trial: 23743559
Drug: Cost analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost analysis for 16 weeks treatment
Trial: 23743559
Drug: Cost analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost analysis for 24 weeks treatment
Trial: 19451304
Drug: KBPA-101 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBPA-101 at 0.1 mg/kg
Trial: 19451304
Drug: KBPA-101 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBPA-101 at 0.4 mg/kg
Trial: 19451304
Drug: KBPA-101 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBPA-101 at 1.2 mg/kg
Trial: 19451304
Drug: KBPA-101 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBPA-101 at 4.0 mg/kg
Trial: 16549451
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of labeled zinc (67Zn) with 50 mg AA (LoZn group)
Trial: 16549451
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of labeled zinc (67Zn) with 50 mg AA (HiZn group)
Trial: 16549451
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zinc with no AA (control)
Trial: 15286543
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing (ODD) of tobramycin (7 mg/kg)
Trial: 15286543
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily dosing (MDD) of tobramycin
Trial: 9331215
Drug: Latanoprost 15
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost 15 microg/ml twice daily
Trial: 9331215
Drug: Latanoprost 50
RxNorm normalized name: Latanoprost 50 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 50 microg/ml once daily
Trial: 8226140
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy to doses of 60.0 Gy, 64.8 Gy, 69.6 Gy, 74.4 Gy, or 79.2 Gy, 1.2 Gy twice daily, 5 days per week.
Trial: 8226140
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy with deviations in treatment time.
Trial: 2418902
Drug: Permixon (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permixon (160 mg bd)
Trial: 29596150
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Oxytocin (24 international units)
Trial: 25497998
Drug: EPG 10
RxNorm normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPG 10 g/day
Trial: 25497998
Drug: EPG 25
RxNorm normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPG 25 g/day
Trial: 25497998
Drug: EPG 40
RxNorm normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPG 40 g/day
Trial: 22190001
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (gel)
Trial: 20157843
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT) - warfarin, ASA, and clopidogrel
Trial: 20157843
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (DT) - ASA and clopidogrel
Trial: 19114376
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose (1 mg/kg) MTW
Trial: 19114376
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose (0.5 mg/kg) MTW
Trial: 15825548
Drug: Repinotan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repinotan 0.5 mg/day
Trial: 15825548
Drug: Repinotan 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repinotan 1.25 mg/day
Trial: 15825548
Drug: Repinotan 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repinotan 2.5 mg/day
Trial: 12861157
Drug: Chlorhexidine vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine vaginal irrigation (200 mL of 0.2% chlorhexidine solution every 6 hours during labor)
Trial: 12861157
Drug: Placebo (sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sterile saline solution every 6 hours during labor)
Trial: 10868308
Drug: Midazolam syrup
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam syrup (0.25, 0.5, or 1.0 mg/kg)
Trial: 10868308
Drug: Midazolam syrup
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam syrup (0.25 to 1.0 mg/kg)
Trial: 10868308
Drug: Midazolam syrup
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam syrup (1.0 mg/kg)
Trial: 27875025
Drug: Hyperinsufflation (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsufflation (15 minutes, twice daily)
Trial: 18155811
Drug: Combined intradermal
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intradermal (ID) BCG and Hepatitis B (HbsAg 10 microg plus BCG suspension 0.1mg)
Trial: 18155811
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) Hepatitis B
Trial: 10817849
Drug: Nitrate+ (patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate+ (patients using nitrate-containing drugs)
Trial: 10817849
Drug: Nitrate- (patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate- (patients not using nitrate-containing drugs)
Trial: 8911839
Drug: Low-dose fentanyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fentanyl anaesthesia + thoracic epidural analgesia
Trial: 949108
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl anaesthesia
Trial: 1687200
Drug: Ismo-Retard 40
RxNorm normalized name: isosorbide mononitrate Extended Release Oral Tablet [Ismo Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ismo-Retard 40 mg
Trial: 1687200
Drug: Ismo-Retard 40
RxNorm normalized name: isosorbide mononitrate Extended Release Oral Tablet [Ismo Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ismo-Retard 40 mg (15 consecutive once-daily doses)
Trial: 1687200
Drug: Imdur 60
RxNorm normalized name: Imdur 60mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imdur 60 mg
Trial: 1687200
Drug: Imdur 60
RxNorm normalized name: Imdur 60mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imdur 60 mg (15 consecutive once-daily doses)
Trial: 6637313
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of indomethacin (Confortid) 50 mg
Trial: 6637313
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 2 mg hydromorphine chloride-atropine (Dilaudid-atropin 1 ml) with a suppository of prochlorperazine (Stemetil) 25 mg
Trial: 30952748
Drug: Standard Temozolomide-based
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard Temozolomide-based therapy
Trial: 25069201
Drug: Warm acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm acupuncture stimulation of TE 5 combined with routine acupuncture and rehabilitation training (30 min, once daily)
Trial: 25069201
Drug: Routine acupuncture
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine acupuncture stimulation of the same acupoints and rehabilitation training (30 min, once daily)
Trial: 17289685
Drug: Three months
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three months of anticoagulation with heparin for five days followed by warfarin (n=369)
Trial: 17289685
Drug: Six months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six months of anticoagulation with heparin for five days followed by warfarin (n=380)
Trial: 11413078
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (200 microgram/d)
Trial: 9327783
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogens (0.625 mg/d)
Trial: 11413078
Drug: Intravenous conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous conjugated estrogens
Trial: 11413078
Drug: Sublingual estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual estradiol
Trial: 9641731
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (r-hGH) treatment at a dosage of 0.2 IU/kg/body weight (0.067 mg/kg) subcutaneously daily for 3 years.
Trial: 9641731
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group 2) with a 1-year observation period followed by a 3-year treatment period.
Trial: 6781189
Drug: Heparin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administered at an early stage
Trial: 6781189
Drug: Heparin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administered at a late stage
Trial: 31124839
Drug: Manual bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual bolus atomization of bupivacaine (1.25 mg/kg diluted in 30 mL normal saline over 30 seconds)
Trial: 26357864
Drug: Clonidine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (25 μg or 50 μg twice daily for 9 weeks)
Trial: 21146661
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (500 mg aspirin, 600 mg clopidogrel, and tirofiban 25 μg/kg bolus and 0.15 μg/kg per minute maintenance infusion for 18 hours)
Trial: 16421011
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy
Trial: 21146661
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (500 mg aspirin and 600 mg clopidogrel)
Trial: 15860853
Drug: 4‐OHT gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐OHT gel (0.5, 1, or 2 mg/d)
Trial: 15860853
Drug: Oral tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tamoxifen (20 mg/d)
Trial: 12475151
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of Rifater (RFT)/Rifinah (RFN)
Trial: 12475151
Drug: Separate regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate regimen of four component drugs (INH, RMP, EMB, PZA)
Trial: 10561143
Drug: Soft Gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft Gelatin Capsule (SGC) formulation
Trial: 10561143
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution formulation
Trial: 1071698
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (chlorothiazide + alpha-methyldopa and/or a beta-adrenoreceptor antagonist as required)
Trial: 28012300
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavior therapy (ICBT)
Trial: 21957933
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help or e-mail therapy (original trial)
Trial: 9159346
Drug: Ciprofloxacin prophylaxis
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin prophylaxis (500 mg orally twice a day)
Trial: 2816477
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives for 30 days
Trial: 2816477
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives for 15 days
Trial: 808126
Drug: Keflex and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keflex and Keflin (therapeutic doses)
Trial: 28851933
Drug: 0.5 ml/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml/kg/min ELO‐MEL‐isoton (osmolarity = 302 mosmol/l) for 60 minutes
Trial: 22161694
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg daily for 14-17 days)
Trial: 16784965
Drug: Chromium-containing milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium-containing milk powder (200 microg/20 g milk powder) twice a day for 16 weeks
Trial: 15572756
Drug: Beta-carotene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (30 mg) and retinyl palmitate (25,000 IU)
Trial: 11230889
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO2) therapy, 100% oxygen for 100 min in a multiplace hyperbaric chamber on 30 occasions over a period of 6 weeks.
Trial: 9425965
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg bupivacaine
Trial: 9425965
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg bupivacaine
Trial: 2850326
Drug: Alfa LMW1
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alfa LMW1 (8,000 I.U. AXa daily for 6 months)
Trial: 23764248
Drug: Same amount
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same amount of intravenous contrast in both CCTA examinations
Trial: 23764248
Drug: 0.7 mL/mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mL/mg body weight of contrast medium (350 mgI/mL) for baseline and follow-up CCTAs
Trial: 21992655
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavior therapy (ICBT) for 10 weeks, guided by an online therapist, focusing on acceptance of symptoms through exposure and mindfulness training.
Trial: 17176013
Drug: Nonoperative therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative therapies
Trial: 11084187
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (15 mg for 8 weeks, then 10 mg for 3 weeks)
Trial: 1281015
Drug: FUT (nafamostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUT (nafamostat mesilate) 2 mg/kg/hr during CPB and 0.2 mg/kg/hr before and after CPB
Trial: 6146752
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg daily for 14 days)
Trial: 27098971
Drug: Integrated, multifaceted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated, multifaceted package of interventions including delayed prescribing, patient decision aids, communication training, commitment to a practice prescribing policy for antibiotics, patient information leaflet, and near patient testing with C-reactive protein.
Trial: 20466698
Drug: Antibiotic impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic impregnated catheters (Bactiseal)
Trial: 20466698
Drug: Conventional catheters
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional catheters with systemic antibiotics
Trial: 18361280
Drug: Individual therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapies